JP2019521155A5 - - Google Patents

Download PDF

Info

Publication number
JP2019521155A5
JP2019521155A5 JP2019501928A JP2019501928A JP2019521155A5 JP 2019521155 A5 JP2019521155 A5 JP 2019521155A5 JP 2019501928 A JP2019501928 A JP 2019501928A JP 2019501928 A JP2019501928 A JP 2019501928A JP 2019521155 A5 JP2019521155 A5 JP 2019521155A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
breast
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019501928A
Other languages
English (en)
Japanese (ja)
Other versions
JP6961675B2 (ja
JP2019521155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2017/050848 external-priority patent/WO2018014116A1/en
Publication of JP2019521155A publication Critical patent/JP2019521155A/ja
Publication of JP2019521155A5 publication Critical patent/JP2019521155A5/ja
Priority to JP2021167806A priority Critical patent/JP7263473B2/ja
Application granted granted Critical
Publication of JP6961675B2 publication Critical patent/JP6961675B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019501928A 2016-07-18 2017-07-13 Ttk阻害剤の固体形態 Active JP6961675B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021167806A JP7263473B2 (ja) 2016-07-18 2021-10-13 Ttk阻害剤の固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
US62/363,424 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021167806A Division JP7263473B2 (ja) 2016-07-18 2021-10-13 Ttk阻害剤の固体形態

Publications (3)

Publication Number Publication Date
JP2019521155A JP2019521155A (ja) 2019-07-25
JP2019521155A5 true JP2019521155A5 (https=) 2020-08-20
JP6961675B2 JP6961675B2 (ja) 2021-11-05

Family

ID=60991755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019501928A Active JP6961675B2 (ja) 2016-07-18 2017-07-13 Ttk阻害剤の固体形態
JP2021167806A Active JP7263473B2 (ja) 2016-07-18 2021-10-13 Ttk阻害剤の固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021167806A Active JP7263473B2 (ja) 2016-07-18 2021-10-13 Ttk阻害剤の固体形態

Country Status (25)

Country Link
US (3) US10584130B2 (https=)
EP (1) EP3484888B1 (https=)
JP (2) JP6961675B2 (https=)
KR (2) KR102537088B1 (https=)
CN (2) CN115093416B (https=)
AU (2) AU2017299850B2 (https=)
BR (1) BR112019000813A2 (https=)
DK (1) DK3484888T3 (https=)
ES (1) ES2945108T3 (https=)
FI (1) FI3484888T5 (https=)
HR (1) HRP20230481T1 (https=)
HU (1) HUE061872T2 (https=)
IL (1) IL264173B2 (https=)
LT (1) LT3484888T (https=)
MA (1) MA45691A (https=)
MX (2) MX385289B (https=)
PL (1) PL3484888T3 (https=)
PT (1) PT3484888T (https=)
RS (1) RS64210B1 (https=)
RU (2) RU2753905C2 (https=)
SG (2) SG10202103332UA (https=)
SI (1) SI3484888T1 (https=)
SM (1) SMT202300156T1 (https=)
TW (2) TWI824313B (https=)
WO (1) WO2018014116A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3484888T3 (pl) 2016-07-18 2023-06-26 University Health Network Stałe postacie inhibitora TTK
KR20240175121A (ko) 2023-06-12 2024-12-19 한국재료연구원 희토류 산화물을 이용한 입계확산물질의 제조방법 및 이를 이용한 R-Fe-B계 영구자석의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100876327B1 (ko) 2001-02-21 2008-12-31 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 진단에서의, 그리고 암에서 치료 표적으로서의 ttk
PT1812440E (pt) * 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP2014503521A (ja) * 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
PL3484888T3 (pl) 2016-07-18 2023-06-26 University Health Network Stałe postacie inhibitora TTK

Similar Documents

Publication Publication Date Title
CY1125855T1 (el) Αναστολεις της ειδικης για τη λυσινη απομεθυλασης-1
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1125127T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
CY1120903T1 (el) Ενωσεις αμινοπυριδυλοξυπυραζολιου
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
JP2015503422A5 (https=)
MX2016010266A (es) Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
GEP20237496B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
IL270717A (en) Biomarkers for diagnosis of lung cancer
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
MX2016011072A (es) Derivado de pirazol amida.
MX375219B (es) Inhibidores de histona demetilasa.
LT3416957T (lt) 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui
HUE050863T2 (hu) Rák és cukorbetegség kezelésére alkalmazható 6-aril-4-(morfolin-4-il)-1H-piridin-2-on vegyületek
EP3583113C0 (en) Immunotherapeutic combination for the treatment of TGF-alpha-expressing lung cancer or TGF-alpha-expressing melanoma
DK3241551T3 (da) Farmaceutisk sammensætning til behandling af kræft, indeholdende lactatmetalsalt
JP2014508784A5 (https=)
JP2017531686A5 (https=)
EP3566705A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF METASTATIC OVARIAN CANCER, ENDOMETRIC CANCER OR BREAST CANCER
EP3359203C0 (en) RECEPTOR-BINDING DOMAINS LIGANDS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF PANCREAS CANCER
JP2019521155A5 (https=)
SG11201912043QA (en) Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions